Comparing trials of glycoprotein IIb/IIIa receptor antagonists

被引：0

作者：

Fox, KAA ^{[1
]}

机构：

[1] Univ Edinburgh, Cardiovasc Res Unit, Royal Infirm Edinburgh, Edinburgh EH3 9YW, Midlothian, Scotland

来源：

EUROPEAN HEART JOURNAL SUPPLEMENTS | 1999年 / 1卷 / 0R期

关键词：

clinical trials; glycoprotein IIb/IIIa inhibitors; PURSUIT; PRISM-PLUS; eptifibatide; tirofiban;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Large, well-designed clinical trials are the basis for determining the effectiveness and safety of pharmacological agents. Clinical trials may appear similar while differing in important aspects. Differences in patient population, end-point definition and trial management make it difficult to draw cross-trial conclusions regarding relative safety and efficacy of different agents. Newly released antiplatelet drugs that antagonize the glycoprotein (GP) IIb/IIIa receptor have been examined in important clinical trials of patients with acute coronary syndromes. The PURSUIT trial of eptifibatide and the PRISM-PLUS trial of tirofiban are presented as examples of trials with important differences in design, and the potential impact of trial design on trial outcome is discussed. In addition, we compare and contrast the results of trials of GP IIb/IIIa inhibitors in percutaneous coronary interventions and address how differences in these trials may have affected their outcomes.

引用

页码：R10 / R17

页数：8

共 50 条

[31] Acute stent thrombosis after early withdrawal of platelet glycoprotein IIb/IIIa antagonists:: Potential rebound prothrombotic effect? [J].

Angiolillo, DJ ;

Sabaté, M ;

Fernández-Ortiz, A ;

Macaya, C .

CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2003, 58 (04) :481-484

[32] Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes [J].

Mak K.H. ;

Moliterno D.J. .

Current Cardiology Reports, 1999, 1 (3) :199-205

[33] Outcomes with changes in prescribing of glycoprotein IIb/IIIa inhibitors in PCI [J].

Dobesh, PP ;

Lanfear, SL ;

Abu-Shanab, JR ;

Lakamp, JE ;

Gowda, S ;

Haikal, MY .

ANNALS OF PHARMACOTHERAPY, 2003, 37 (10) :1375-1380

[34] The use of glycoprotein IIb/IIIa inhibitors in elective PCI - A systematic review and meta-analysis of randomised trials [J].

Brieger, Daniel G. ;

Rao, Karan ;

Nagaraja, Vinayak ;

Bhindi, Ravinay ;

Allahwala, Usaid K. .

VASCULAR PHARMACOLOGY, 2025, 159

[35] Contemporary use of glycoprotein IIb/IIIa inhibitors [J].

Kristensen, Steen Dalby ;

Wuertz, Morten ;

Grove, Erik Lerkevang ;

De Caterina, Raffaele ;

Huber, Kurt ;

Moliterno, David J. ;

Neumann, Franz-Josef .

THROMBOSIS AND HAEMOSTASIS, 2012, 107 (02) :215-224

[36] Glycoprotein IIb/IIIa inhibitors: The resurgence of tirofiban [J].

King, Shawn ;

Short, Marintha ;

Harmon, Cassidy .

VASCULAR PHARMACOLOGY, 2016, 78 :10-16

[37] The Glycoprotein IIb/IIIa Inhibitor Wars An Update [J].

Berger, Peter B. .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2010, 56 (06) :476-478

[38] Intravenous GP IIb/IIIa receptor antagonists: A new direction as adjunct antiplatelet therapy [J].

不详 .

Drugs & Therapy Perspectives, 1999, 14 (11) :1-7

[39] Glycoprotein IIb/IIIa receptor anatagonists: A comparative review of their use in percutaneous coronary intervention [J].

Can M. Nguyen ;

Robert A. Harrington .

American Journal of Cardiovascular Drugs, 2003, 3 (6) :423-436

[40] Low incidence of paradoxical platelet activation by glycoprotein IIb/IIIa inhibitors [J].

Weber, AA ;

Meila, D ;

Jacobs, C ;

Weber, S ;

Kelm, M ;

Strauer, BE ;

Zotz, RB ;

Scharf, RE ;

Schrör, K .

THROMBOSIS RESEARCH, 2002, 106 (01) :25-29

← 1 2 3 4 5 →